Profil
Eric Pauly has worked as a Director at Hepatic Cell Therapy Support SA since 2020 and is currently the Head of Operations & CMC at Cellaïon SA since 2022.
Postes actifs de Eric Pauly
| Sociétés | Poste | Début |
|---|---|---|
Hepatic Cell Therapy Support SA
 Hepatic Cell Therapy Support SA BiotechnologyHealth Technology Part of Catalent, Inc., Hepatic Cell Therapy Support SA is a cell therapy manufacturing facility. The company is based in Charleroi, Belgium. Founded in 2011, the Belgian company operates as a cell therapy manufacturing facility. Hepatic Cell Therapy Support was acquired by Catalent, Inc. from PROMETHERA Biosciences SA on May 06, 2021 for $18.25 million. | Directeur/Membre du Conseil | 15/09/2020 |
Cellaïon SA
 Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Directeur des opérations | 01/01/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Hepatic Cell Therapy Support SA
Hepatic Cell Therapy Support SA BiotechnologyHealth Technology Part of Catalent, Inc., Hepatic Cell Therapy Support SA is a cell therapy manufacturing facility. The company is based in Charleroi, Belgium. Founded in 2011, the Belgian company operates as a cell therapy manufacturing facility. Hepatic Cell Therapy Support was acquired by Catalent, Inc. from PROMETHERA Biosciences SA on May 06, 2021 for $18.25 million. | Health Technology |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Health Technology |